119 related articles for article (PubMed ID: 15009534)
1. Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1.
Sundaram R; Beebe M; Kaumaya PT
J Pept Res; 2004 Feb; 63(2):132-40. PubMed ID: 15009534
[TBL] [Abstract][Full Text] [Related]
2. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
[TBL] [Abstract][Full Text] [Related]
3. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies.
Sundaram R; Lynch MP; Rawale SV; Sun Y; Kazanji M; Kaumaya PT
J Biol Chem; 2004 Jun; 279(23):24141-51. PubMed ID: 15060075
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
[TBL] [Abstract][Full Text] [Related]
5. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
[TBL] [Abstract][Full Text] [Related]
6. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
[TBL] [Abstract][Full Text] [Related]
7. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
[TBL] [Abstract][Full Text] [Related]
8. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
[TBL] [Abstract][Full Text] [Related]
10. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
[TBL] [Abstract][Full Text] [Related]
11. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
Hadlock KG; Rowe J; Foung SK
J Virol; 1999 Feb; 73(2):1205-12. PubMed ID: 9882322
[TBL] [Abstract][Full Text] [Related]
12. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
[TBL] [Abstract][Full Text] [Related]
13. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
[TBL] [Abstract][Full Text] [Related]
14. Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101.
Kitze B; Usuku K; Yamano Y; Yashiki S; Nakamura M; Fujiyoshi T; Izumo S; Osame M; Sonoda S
Clin Exp Immunol; 1998 Feb; 111(2):278-85. PubMed ID: 9486393
[TBL] [Abstract][Full Text] [Related]
15. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
[TBL] [Abstract][Full Text] [Related]
16. Development and Evaluation of a Novel ELISA for Detection of Antibodies against HTLV-I Using Chimeric Peptides.
Mosadeghi P; Heydari-Zarnagh H
Iran J Allergy Asthma Immunol; 2018 Apr; 17(2):144-150. PubMed ID: 29757587
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cell-free human T-cell leukemia virus type 1 infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein.
Jinno A; Haraguchi Y; Shiraki H; Hoshino H
J Virol; 1999 Nov; 73(11):9683-9. PubMed ID: 10516085
[TBL] [Abstract][Full Text] [Related]
18. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.
Palker TJ; Riggs ER; Spragion DE; Muir AJ; Scearce RM; Randall RR; McAdams MW; McKnight A; Clapham PR; Weiss RA
J Virol; 1992 Oct; 66(10):5879-89. PubMed ID: 1326649
[TBL] [Abstract][Full Text] [Related]
19. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.
Hadlock KG; Rowe J; Perkins S; Bradshaw P; Song GY; Cheng C; Yang J; Gascon R; Halmos J; Rehman SM; McGrath MS; Foung SK
J Virol; 1997 Aug; 71(8):5828-40. PubMed ID: 9223472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
